30 Healthy People |
30 Healthy People research study
What is the primary objective of this study?
Currently, drugs commonly used for antiplatelet are aspirin and clopidogrel when encountering stroke or coronary heart disease. In this study, we would use VASP assay and thromboelastograph with platelet mapping assay kit to evaluate the antiplatelet resistance in general population and the relationship between clopidogrel and proton pump inhibitor.
Who is eligible to participate?
Inclusion Criteria: - 30 Healthy people, without major systemic disease, not under medication treatment Exclusion Criteria: - Systemic disease, under medication control with NSAID, anticoagulants, taking antiplatelet drugs before entering trial, Chinese herb, pregnant or breast feeding woman
Which medical condition, disease, disorder, syndrome, illness, or injury is researched?
30 Healthy People
Interventions can include giving participants drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available or noninvasive approaches such as surveys, education, and interviews.
Drug:Clopidogrel and proton pump inhibitorsbaseline detection --> clopidogrel 75 mg PO QD for 1 week --> clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus pantoprazole 40mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week --> 1 week washout --> aspirin 100mg PO QD for 1 week
Research studies and clinical trials typically have two or more research arms. An arm is a group of people who receive the same treatment in the study.
Clopidogrel and proton pump inhibitorsall participating healthy people should receive clopidogrel and 3 kinds of PPI sequentially with one week interval between each PPI.
Start Date: May 2008
Completed Date: October 2010
Phase: Phase 4
Study sponsors, principal investigator, and references
Principal Investigator: Fu-Tien Chiang, MD, Phd
Lead Sponsor: National Taiwan University Hospital
Collaborator: Haemonetics Corporation